Selank Intranasal Spray: Non-Sedating Anxiolytic Delivery
Research on intranasal administration of the tuftsin-derived peptide for anxiety and immune modulation
Source: https://indexalabs.com/blog/selank-intranasal-spray-anxiolytic-research Abstract: Selank intranasal spray provides rapid anxiolytic effects without the sedation or dependence associated with benzodiazepines. This guide examines the clinical evidence, pharmacokinetics, and immunomodulatory benefits of the approved Russian nasal formulation.
1. Introduction to Intranasal Selank
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is approved in Russia as a 0.15% intranasal solution for the treatment of generalized anxiety disorder and neurasthenia. The nasal spray format is the primary clinical delivery method, chosen for its rapid onset of anxiolytic effects and excellent patient compliance.
The intranasal formulation delivers Selank directly to the CNS via the nose-to-brain pathway, enabling GABA modulation and BDNF upregulation within minutes. This guide focuses specifically on the intranasal format and its advantages over parenteral administration.
2. Intranasal Anxiolytic Mechanisms
2.1 Rapid GABA Enhancement Intranasal delivery enables rapid GABAergic modulation in the amygdala and prefrontal cortex, producing anxiolytic effects within 10-15 minutes — significantly faster than oral anxiolytics.
2.2 BDNF Upregulation Direct CNS delivery maximizes BDNF expression in the hippocampus, supporting both acute anxiolysis and long-term neuroplastic adaptation.
2.3 Serotonin Modulation Intranasal Selank modulates serotonin metabolism in brain regions associated with mood regulation, contributing to sustained anxiolytic effects.
2.4 Enkephalin Stabilization Inhibition of enkephalin-degrading enzymes in the CNS prolongs endogenous opioid signaling, providing an additional anxiolytic mechanism without addictive potential.
3. Clinical Evidence
3.1 Generalized Anxiety Disorder Double-blind, placebo-controlled trials demonstrated that intranasal Selank (0.15% solution, 3 sprays per nostril, 3x daily) significantly reduced Hamilton Anxiety Scale scores after 14 days of treatment, with effects comparable to phenazepam (a benzodiazepine) but without cognitive impairment.
3.2 Benzodiazepine Comparison Head-to-head studies showed equivalent anxiolytic efficacy to low-dose benzodiazepines with critical advantages: no sedation, no psychomotor impairment, no tolerance development, and no withdrawal symptoms upon discontinuation.
3.3 Immune Modulation Uniquely among anxiolytics, intranasal Selank demonstrated immunomodulatory effects — normalizing IL-6, TNF-α, and interferon-γ levels in patients with anxiety-associated immune dysregulation.
3.4 Cognitive Co-Benefits Anxious patients treated with intranasal Selank showed improved attention, memory, and processing speed — the opposite of the cognitive dulling seen with benzodiazepines.
4. Research Protocols & Format Advantages
4.1 Spray Format The 10ml nasal spray bottle provides approximately 60 sprays at ~900mcg per actuation. The format ensures consistent dosing and optimal mucosal deposition.
4.2 Dual Activity Profile The intranasal format uniquely positions Selank as both a CNS-active anxiolytic and a systemically absorbed immunomodulator, as the tuftsin backbone retains immune-enhancing properties through systemic absorption.
4.3 No Dependence Liability Extensive clinical use has confirmed zero dependence potential. Abrupt discontinuation produces no rebound anxiety or withdrawal symptoms — a critical differentiator from benzodiazepines.
4.4 Storage & Stability Store at 2-8°C (refrigerated). The reconstituted nasal solution maintains stability for 30 days once opened. Protect from direct light and temperature fluctuations.